MedTrace Logo

Safety and Efficacy of Varying Methods of ALV003 Administration for the Treatment of Celiac Disease

NCT01255696 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 61

Last updated 2012-08-06

No results posted yet for this study

Summary

A phase 2a study to evaluate the safety and efficacy of ALV003 to treat celiac disease.

Conditions

Interventions

BIOLOGICAL

ALV003

BIOLOGICAL

ALV003 placebo

Sponsors & Collaborators

  • Alvine Pharmaceuticals Inc.

    lead INDUSTRY

Principal Investigators

  • Marja-Leena Lähdeaho, MD · FINN-MEDI Research Oy

  • Markku Mäki, MD, PhD · Tampere University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2011-05-31
Completion
2011-06-30

Countries

  • Finland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01255696 on ClinicalTrials.gov